Cargando…

Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model

Combined treatment with 5-aminolevulinic acid (5-ALA) and X-rays improves tumor suppression in vivo. This is because the accumulated protoporphyrin IX from 5-ALA enhances the generation of ROS by the X-ray irradiation. In the present study, a high-energy medical linear accelerator was used instead o...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Junko, Murakami, Mami, Mori, Takashi, Iwahashi, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807383/
https://www.ncbi.nlm.nih.gov/pubmed/29426920
http://dx.doi.org/10.1038/s41598-018-21152-z
_version_ 1783299254259810304
author Takahashi, Junko
Murakami, Mami
Mori, Takashi
Iwahashi, Hitoshi
author_facet Takahashi, Junko
Murakami, Mami
Mori, Takashi
Iwahashi, Hitoshi
author_sort Takahashi, Junko
collection PubMed
description Combined treatment with 5-aminolevulinic acid (5-ALA) and X-rays improves tumor suppression in vivo. This is because the accumulated protoporphyrin IX from 5-ALA enhances the generation of ROS by the X-ray irradiation. In the present study, a high-energy medical linear accelerator was used instead of a non-medical low energy X-ray irradiator, which had been previously used. Tumor-bearing mice implanted with B16-BL6 melanoma cells were treated with fractionated doses of irradiation (in total, 20 or 30 Gy), using two types of X-ray irradiator after 5-ALA administration. Suppression of tumor growth was enhanced with X-ray irradiation in combination with 5-ALA treatment compared with X-ray treatment alone, using both medical and non-medical X-ray irradiators. 5-ALA has been used clinically for photodynamic therapy. Thus, “radiodynamic therapy”, using radiation from medical linacs as a physical driving force, rather than the light used in photodynamic therapy, may have potential clinical applications.
format Online
Article
Text
id pubmed-5807383
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-58073832018-02-14 Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model Takahashi, Junko Murakami, Mami Mori, Takashi Iwahashi, Hitoshi Sci Rep Article Combined treatment with 5-aminolevulinic acid (5-ALA) and X-rays improves tumor suppression in vivo. This is because the accumulated protoporphyrin IX from 5-ALA enhances the generation of ROS by the X-ray irradiation. In the present study, a high-energy medical linear accelerator was used instead of a non-medical low energy X-ray irradiator, which had been previously used. Tumor-bearing mice implanted with B16-BL6 melanoma cells were treated with fractionated doses of irradiation (in total, 20 or 30 Gy), using two types of X-ray irradiator after 5-ALA administration. Suppression of tumor growth was enhanced with X-ray irradiation in combination with 5-ALA treatment compared with X-ray treatment alone, using both medical and non-medical X-ray irradiators. 5-ALA has been used clinically for photodynamic therapy. Thus, “radiodynamic therapy”, using radiation from medical linacs as a physical driving force, rather than the light used in photodynamic therapy, may have potential clinical applications. Nature Publishing Group UK 2018-02-09 /pmc/articles/PMC5807383/ /pubmed/29426920 http://dx.doi.org/10.1038/s41598-018-21152-z Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Takahashi, Junko
Murakami, Mami
Mori, Takashi
Iwahashi, Hitoshi
Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model
title Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model
title_full Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model
title_fullStr Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model
title_full_unstemmed Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model
title_short Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model
title_sort verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807383/
https://www.ncbi.nlm.nih.gov/pubmed/29426920
http://dx.doi.org/10.1038/s41598-018-21152-z
work_keys_str_mv AT takahashijunko verificationofradiodynamictherapybymedicallinearacceleratorusingamousemelanomatumormodel
AT murakamimami verificationofradiodynamictherapybymedicallinearacceleratorusingamousemelanomatumormodel
AT moritakashi verificationofradiodynamictherapybymedicallinearacceleratorusingamousemelanomatumormodel
AT iwahashihitoshi verificationofradiodynamictherapybymedicallinearacceleratorusingamousemelanomatumormodel